These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 10100713)

  • 41. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
    Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
    Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.
    Jazirehi AR; Bonavida B
    Methods Mol Biol; 2011; 731():407-19. PubMed ID: 21516425
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma.
    Wu L; Wang C; Zhang D; Zhang X; Qian W; Zhao L; Wang H; Li B; Guo Y
    Cancer Lett; 2010 Jun; 292(2):208-14. PubMed ID: 20056316
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].
    Tobinai K
    Nihon Rinsho; 2002 Mar; 60(3):468-72. PubMed ID: 11904960
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Cutaneous B-cell lymphoma treatment with rituximab: two cases].
    Viguier M; Bachelez H; Brice P; Rivet J; Dubertret L
    Ann Dermatol Venereol; 2002 Oct; 129(10 Pt 1):1152-5. PubMed ID: 12442128
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
    Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N
    J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Rituximab and hematological malignancy].
    Hatake K; Mishima Y; Terui Y
    Nihon Rinsho; 2004 Jul; 62(7):1321-4. PubMed ID: 15283150
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-CD20-based therapy of B cell lymphoma: state of the art.
    Kosmas C; Stamatopoulos K; Stavroyianni N; Tsavaris N; Papadaki T
    Leukemia; 2002 Oct; 16(10):2004-15. PubMed ID: 12357351
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
    Maeda LS; Advani RH
    Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma.
    Tobinai K
    Int J Clin Oncol; 2003 Aug; 8(4):212-23. PubMed ID: 12955576
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.
    Kennedy GA; Tey SK; Cobcroft R; Marlton P; Cull G; Grimmett K; Thomson D; Gill D
    Br J Haematol; 2002 Nov; 119(2):412-6. PubMed ID: 12406079
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders.
    Musto P; D'Auria F
    Expert Opin Biol Ther; 2011 May; 11(5):551-7. PubMed ID: 21385115
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
    Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Loss of CD20 expression in relapsed lymphomas after rituximab therapy.
    Haidar JH; Shamseddine A; Salem Z; Mrad YA; Nasr MR; Zaatari G; Bazarbachi A
    Eur J Haematol; 2003 May; 70(5):330-2. PubMed ID: 12694172
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [One amino acid mutation in an anti-CD20 antibody fragment that affects the yield bacterial secretion and the affinity].
    Liu YX; Xiong DS; Fan DM; Shao XF; Xu YF; Zhu ZP; Yang CZ
    Sheng Wu Gong Cheng Xue Bao; 2003 May; 19(3):272-6. PubMed ID: 15969005
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab)].
    Tobinai K
    Nihon Rinsho; 2002 Jan; 60(1):95-9. PubMed ID: 11808346
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.
    Seliem RM; Freeman JK; Steingart RH; Hasserjian RP
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):18-23. PubMed ID: 16540725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.